Views & Analysis How pharma can thrive in the digital era December marks the one year anniversary of the U.S.
News Regeneron's three-monthly gMG drug Livsayis cleared by FDA Regeneron has joined the crowded gMG market with an siRNA-based therapy, Livsayis, that only needs to be dosed four times a year.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.